Proteasome: An emerging target for cancer therapy

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 475-481

  Zavrski, Ivana ^a   Jakob, Christian ^a   Schmid, Peter ^a   Krebbel, Holger ^a   Kaiser, Martin ^a   Fleissner, Claudia ^a   Rosche, Marleen ^a   Possinger, Kurt ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bortezomib; Cancer; Multiple myeloma; Proteasome; PS 341

Indexed keywords

26S PROTEASOME; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; THREONINE PROTEINASE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CATALYSIS; CELL CYCLE; CELL CYCLE ARREST; CELL FUNCTION; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE COURSE; DOWN REGULATION; DRUG APPROVAL; DRUG POTENTIATION; DRUG TARGETING; EUKARYOTIC CELL; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME;

EID: 18844381179     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00002     Document Type: Review

References (74)

1. Tanaka K, Yoshimura T, Kumatori A, Ichihara A, Ikai A, Nishigai M, et al. Proteasomes (multi-protease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells. J Biol Chem 1988; 263:16209-16217.
2. Knuehl C, Seelig A, Brecht B, Henklein P, Kloetzel PM. Functional analysis of eukaryotic 20S proteasome nuclear localization signal. Exp Cell Res 1996; 225:67-74.
3. Walz J, Erdmann A, Kania M, Typke D, Koster AJ, Baumeister W. 26S proteasome structure revealed by three-dimensional electron microscopy. J Struct Biol 1998; 121:19-29.
4. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 1987; 262: 8303-8313.
5. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8:333-3338.
6. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001; 311:543-548.
7. Hoffman L, Rechsteiner M. Activation of the multicatalytic protease. The 11 S regulator and 20 S ATPase complexes contain distinct 30-kilodalton submits. J Biol Chem 1994; 269:16890-16895.
8. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996; 35:3899-3908.
9. Seeger M, Ferrell K, Dubiel W. The 26S proteasome: a dynamic structure. Mol Biol Rep 1997; 24:83-88.
10. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87:7071-7075.
11. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6:185-197.
12. Zhang Y, Wang Z, Liu DX, Pagano M, Ravid K. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem 1998; 273:1387-1392.
13. Cooper KF, Mallory MJ, Strich R. Oxidative stress-induced destruction of the yeast C-type cyclin Ume3p requires phosphatidylinositol-specific phospholipase C and the 26S proteasome. Mol Cell Biol 1999; 19: 3338-3348.
14. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11:957-972.
15. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10:1979-1990.
16. Thullberg M, Bartek J, Lukas J. Ubiquitin/proteasome-mediated degradation of p19INK4d determines its periodic expression during the cell cycle. Oncogene 2000; 19:2870-2876.
17. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21 WAF1/CIP1 expression, Biochem Biophys Res Commun 1996; 227:564-569.
18. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-685.
19. Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. J Biol Chem 1999; 274:12197-12200.
20. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56: 2649-2654.
21. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56:4620-4624.
22. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 1991; 88:139-143.
23. Stancovski I, Gonen H, Orian A, Schwartz AL, Ciechanover A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol Cell Biol 1995; 15:7106-7116.
24. Nakajima T, Morita K, Ohi N, Arai T, Nozaki N, Kikuchi A, et al. Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996; 271:24842-24849.
25. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998; 9:79-84.
26. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288:874-877.
27. Kho CJ, Huggins GS, Endege WO, Hsieh CM, Lee ME, Haber E. Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A. J Biol Chem 1997; 272:3845-3851.
28. Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 1997; 94:2221-2226.
29. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996; 273:1717-1719.
30. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78:773-785.
31. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994; 13: 5433-5441.
32. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115:279-286.
33. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100:2961-2969.
34. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91:4624-4631.
35. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274:784-787.
36. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246.
37. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-2380.
38. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-16647.
39. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268:726-731.
40. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack7 TA, Melandri FD, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997; 272:182-188.
41. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 1999; 96:5418-5422.
42. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
43. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5:2638-2645.
44. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T. et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000; 6:916-923.
45. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-1428.
46. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003; 113:88-95.
47. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-3728.
48. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 1999; 443:181-186.
49. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001; 113:126-135.
50. Naujokat C, Sezer O, Zinke H, Ledere A, Hauptmann S, Possinger K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000; 65:221-236.
51. Yamada Y, Sugahara K, Tsuruda K, Nohda K, Mori N, Hata T, et al. Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines. Eur J Haematol 2000; 64: 315-322.
52. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
53. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9:1136-1144.
54. Zavrski I, Naujokat C, Niemoller K, Jakob C, Heider U, Langelotz C, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003; 129:383-391.
55. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997; 272:24159-24164.
56. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-3540.
57. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420-4427
58. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10:3371-3376.
59. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-2121.
60. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-2511.
61. Davies M, Lara PN, Lau DH, Mack PC, Gumerlock PH, Gandara DR, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. Proc Am Soc Clin Oncol 2004; 23:639 (abstr 7106).
62. Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE, et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004; 23:334 (abstr 4089).
63. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
64. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
65. Cavenagh JD, Curry N, Stec J, Drake M, Morris TCM, Agrawal S, et al. PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM). Proc Am Soc Clin Oncol 2004; 23:568 (abstr 6550).
66. Jagannath S, Durie B, Wolf J, Camacho E, Irwin D, Lutzky J, et al. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Proc Am Soc Clin Oncol 2004; 23:568 (abstr 6551).
67. Richardson P, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib versus dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. Proc Am Soc Clin Oncol 2004; 23:558 (abstr 6511).
68. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-6118.
69. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, et al. Phase Ii trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004; 22:115-119.
70. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720-3725.
71. Dragovich T, Lenz HJ, Rocha Lima CMS, Kozuch P, Hochster H, et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer: interim analysis results from phase 2b study. Proc Am Soc Clin Oncol 2004; 23:268 (abstr 3591).
72. Brown J, Von Roenn J, O'Regan R, Bergan R, Badve S, Rademaker A, et al. A phase II study of the proteasome inhibitor PS-341 in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 23:13 (abstr 546).
73. Fanucchi MP, Belt RJ, Fossella FV, Natale RB, Robert F, Fidias P, et al. Phase 2 study of bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 2004; 23:640 (abstr 7107).
74. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, et al. Update on a phase 2 study of bortezomib in patients with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). Proc Am Soc Clin Oncol 2004; 23:575 (abstr 6581).